Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Zyceva-150 Erlotinib Tablets 150mg:
Zyceva-150 Erlotinib Tablets 150mg are integral to the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer, providing targeted therapy to inhibit cancer cell growth and improve patient prognosis.
Uses of Zyceva-150 Erlotinib Tablets 150mg:
Non-Small Cell Lung Cancer (NSCLC): Delays cancer progression and improves survival rates.
Pancreatic Cancer: Controls tumor growth and enhances treatment outcomes.
Targeted Therapy: Blocks specific proteins involved in cancer cell proliferation.
Benefits of Zyceva-150 Erlotinib Tablets 150mg:
Precision Treatment: Targets cancer cells while sparing healthy tissues.
Extended Survival: Improves overall survival rates in advanced cancer stages.
Clinically Proven: Demonstrates efficacy in clinical trials and real-world settings.
Mechanism of Action of Zyceva-150 Erlotinib Tablets 150mg:
Erlotinib inhibits epidermal growth factor receptor (EGFR), a protein that promotes cancer cell growth. By blocking EGFR, Zyceva-150 Erlotinib Tablets 150mg effectively slow down tumor growth and spread, providing therapeutic benefits for patients with NSCLC and pancreatic cancer.
Beside this well also export in other countries